- Written communication by the subject company relating to a third party tender offer (SC14D9C)
06 Avril 2012 - 12:07PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(Rule 14d-101)
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
ALLOS THERAPEUTICS, INC.
(Name of Subject Company)
ALLOS THERAPEUTICS, INC.
(Name of Persons Filing Statement)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
019777101
(CUSIP Number of Class of Securities)
Paul Berns
Chief Executive Officer
11080 CirclePoint Road, Suite 200
Westminster, CO 80020
(303) 426-6262
(Name, address and telephone number of persons authorized to receive
notices and communications on behalf of the persons filing statement)
With copies to:
Peter F. Kerman
Joshua M. Dubofsky
Latham & Watkins LLP
140 Scott Drive
Menlo Park, California 94025-3656
(650) 328-4600
x
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
The information set forth under Items 1.01, 5.02 and 9.01 of the Current Report on Form 8-K filed by Allos Therapeutics, Inc. on April 6, 2012 (including all exhibits attached thereto) is incorporated herein by reference.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur